Skip to main content
Log in

Donepezil in patients with severe alzheimer’s disease

  • Clinical Trials Report
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Feldman H, Gauthier S, Hecker J, et al.: Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology 2004, 63:644–650.

    PubMed  CAS  Google Scholar 

  2. Feldman H, Gauthier S, Hecker J, et al.: Efficacy and safety of donepezil in patients with more severe Alzheimer’s disease: a subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry 2005, 20:559–569.

    Article  PubMed  Google Scholar 

  3. Feldman H, Gauthier S, Hecker J, et al.: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001, 57:613–620.

    PubMed  CAS  Google Scholar 

  4. Tariot PN, Cummings JL, Katz IR, et al.: A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc 2001, 49:1590–1599.

    Article  PubMed  CAS  Google Scholar 

  5. Reisberg B, Doody R, Stoffier A, et al.: Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003, 348:1333–1341.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marder, K. Donepezil in patients with severe alzheimer’s disease. Curr Neurol Neurosci Rep 6, 363–364 (2006). https://doi.org/10.1007/s11910-996-0015-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-996-0015-x

Keywords

Navigation